Microbot Medical Inc (MBOT)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$1.14+4.59%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · MBOT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 817.5% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 29 industry peers
MBOT — CFO transition
Dated 2026-08-07
Chief Financial Officer — Rachel Vaknin: Salary increase for the Chief Financial Officer.
Why it matters: Q2 cost of revenue rose, and gross profit was negative $643,000. Lower costs would show that the planned cuts are taking hold.
Supportive ifThe November 11 report shows cost of revenue below Q2's $884,000, with gross profit above negative $643,000.
Worry ifQ3 cost of revenue is at least $884,000, or gross profit is at or below negative $643,000.
Why it matters: The sales footprint grew from four territories to eight in Q2. Reaching 12 would show that the company is extending its U.S. reach.
Supportive ifBy December 31, Microbot reports 12 U.S. sales territories are active.
Worry ifAt year-end, Microbot reports fewer than 12 active U.S. sales territories.
Why it matters: The company agreed to add a second site to support demand and lower costs. A production start would show progress beyond planning.
Supportive ifThe company names a start date or confirms the Sanmina site is making LIBERTY systems.
Worry ifThe company reports that the Sanmina site is delayed, or gives no start date by the next earnings report.
Why it matters: Q2 revenue more than doubled from Q1, but the company remains loss-making. Another rise would show that sales growth is continuing.
Supportive ifIn the November 11 report, Q3 revenue is above $241,000 and procedure volume also rises from Q2.
Worry ifQ3 revenue is $241,000 or less, or procedure volume falls from Q2.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$168 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $632 loss on $10,000 · 6.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,701 loss on $10,000 · 67.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A CE Mark would clear a key step toward sales in Europe. A delay or refusal would leave that market out of reach for now.
Watch forMicrobot says LIBERTY has received a CE Mark.
Also watch forMicrobot reports that the CE Mark review is delayed, or that approval was denied.